These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 18511442)

  • 1. Comment on: Thallas-Bonke et al. (2008) Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway: Diabetes 57:460-469, 2008.
    Yamagishi S
    Diabetes; 2008 Jun; 57(6):e13; author reply e14. PubMed ID: 18511442
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
    Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
    Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and advanced glycation in diabetic nephropathy.
    Coughlan MT; Mibus AL; Forbes JM
    Ann N Y Acad Sci; 2008 Apr; 1126():190-3. PubMed ID: 18448815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.
    Bolton WK; Cattran DC; Williams ME; Adler SG; Appel GB; Cartwright K; Foiles PG; Freedman BI; Raskin P; Ratner RE; Spinowitz BS; Whittier FC; Wuerth JP;
    Am J Nephrol; 2004; 24(1):32-40. PubMed ID: 14685005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of a novel inhibitor of advanced glycation.
    Forbes JM; Soulis T; Thallas V; Panagiotopoulos S; Long DM; Vasan S; Wagle D; Jerums G; Cooper ME
    Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
    McLennan SV; Kelly DJ; Schache M; Waltham M; Dy V; Langham RG; Yue DK; Gilbert RE
    Kidney Int; 2007 Aug; 72(4):481-8. PubMed ID: 17554258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor.
    Koike N; Takamura T; Kaneko S
    Life Sci; 2007 Apr; 80(18):1721-8. PubMed ID: 17346751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.
    Li H; Zheng X; Wang H; Zhang Y; Xin H; Chen X
    Eur J Pharmacol; 2010 Feb; 627(1-3):340-7. PubMed ID: 19895808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
    Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
    Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats.
    Xu M; Dai DZ; Dai Y
    Am J Nephrol; 2009; 29(3):252-6. PubMed ID: 18802327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats.
    Ito D; Cao P; Kakihana T; Sato E; Suda C; Muroya Y; Ogawa Y; Hu G; Ishii T; Ito O; Kohzuki M; Kiyomoto H
    PLoS One; 2015; 10(9):e0138037. PubMed ID: 26379244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
    Miyata T; Yamamoto M; Izuhara Y
    Ann N Y Acad Sci; 2005 Jun; 1043():740-9. PubMed ID: 16037301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
    Nam SM; Lee MY; Koh JH; Park JH; Shin JY; Shin YG; Koh SB; Lee EY; Chung CH
    Diabetes Res Clin Pract; 2009 Feb; 83(2):176-82. PubMed ID: 19111363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of NADPH oxidase inhibitor in diabetic nephropathy.
    Asaba K; Tojo A; Onozato ML; Goto A; Quinn MT; Fujita T; Wilcox CS
    Kidney Int; 2005 May; 67(5):1890-8. PubMed ID: 15840036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats.
    Jeyabal PV; Kumar R; Gangula PR; Micci MA; Pasricha PJ
    Neurogastroenterol Motil; 2008 Mar; 20(3):253-61. PubMed ID: 17971026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
    Coughlan MT; Thallas-Bonke V; Pete J; Long DM; Gasser A; Tong DC; Arnstein M; Thorpe SR; Cooper ME; Forbes JM
    Endocrinology; 2007 Feb; 148(2):886-95. PubMed ID: 17110423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
    Coughlan MT; Cooper ME; Forbes JM
    Ann N Y Acad Sci; 2005 Jun; 1043():750-8. PubMed ID: 16037302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
    Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
    Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.